Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the efficacy of aflibercept for the treatment of diabetic macular edema via a treat-and-extend regimen. Methods: This prospective, single-center, open-label, interventional study involved 30 patients with a best-corrected visualacuity (BCVA) ≤0.6 and a central retinal thickness (CRT) ≥300 μm. The enrolled eyes each received a monthly intravitreal afliberceptinjection until the CRT decreased below 300 μm, upon which the administration interval was extended for 1 monthuntil the CRT once again increased to ≥300 μm. Main outcome measures were median BCVA and CRT at 6 and 12 monthsafter initiation of treatment via last observation carried forward analysis, the median number of injections over the 12months, and the effects on the diabetic retinopathy severity scale (DRSS) score of the patients who completed the 12-monthfollow-up period. Results: Of the 30 enrolled patients, 29 and 25 respectively completed the 6- and 12-month follow-up examinations. Frombaseline to 6 and 12 months after treatment initiation, the median BCVA (logarithm of the minimum angle of resolution) significantlyimproved from 0.52 to 0.30 and 0.35, respectively, and the median CRT significantly decreased from 439.5 to 268.5and 249.0 μm, respectively. The median number of injections over the 12-month follow-up period was 6.0. Compared tobaseline, the DRSS score at 12 months was improved by 2 steps in 16% of patients; in no cases did the DRSS score worsen orimprove by three steps or more. Conclusions: When administered in a treat-and-extend regimen, aflibercept is an effective treatment option for diabeticmacular edema.
Abstract
Purpose: To investigate the efficacy of aflibercept for the treatment of diabetic macular edema via a treat-and-extend regimen. Methods: This prospective, single-center, open-label, interventional study involved 30 patients with a best-corrected visualacuity (BCVA) ≤0.6 and a central retinal thickness (CRT) ≥300 μm. The enrolled eyes each received a monthly intravitreal afliberceptinjection until the CRT decreased below 300 μm, upon which the administration interval was extended for 1 monthuntil the CRT once again increased to ≥300 μm. Main outcome measures were median BCVA and CRT at 6 and 12 monthsafter initiation of treatment via last observation carried forward analysis, the median number of injections over the 12months, and the effects on the diabetic retinopathy severity scale (DRSS) score of the patients who completed the 12-monthfollow-up period. Results: Of the 30 enrolled patients, 29 and 25 respectively completed the 6- and 12-month follow-up examinations. Frombaseline to 6 and 12 months after treatment initiation, the median BCVA (logarithm of the minimum angle of resolution) significantlyimproved from 0.52 to 0.30 and 0.35, respectively, and the median CRT significantly decreased from 439.5 to 268.5and 249.0 μm, respectively. The median number of injections over the 12-month follow-up period was 6.0. Compared tobaseline, the DRSS score at 12 months was improved by 2 steps in 16% of patients; in no cases did the DRSS score worsen orimprove by three steps or more. Conclusions: When administered in a treat-and-extend regimen, aflibercept is an effective treatment option for diabeticmacular edema.
참고문헌 (23)
- Murata T, "Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels", Ophthalmic Res, 27, pp.48~52 (1995)
- Diabetic Retinopathy Clinical Research Network, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema", N Engl J Med, 372, pp.1193~1203 (2015)
- Lanzetta P, "Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases", Graefes Arch Clin Exp Ophthalmol, 255, pp.1259~1273 (2017)
- Sugimoto M, "Clinical preferences and trends of anti-vascular endothelial growth factor treatments for diabetic macular edema in Japan", J Diabetes Investig, 10, pp.475~483 (2019)
- Nguyen QD, "Ranibizumab for diabetic macular edema : results from 2 phase III randomized trials : RISE and RIDE", Ophthalmology, 119, pp.789~801 (2012)
- Korobelnik JF, "Intravitreal aflibercept for diabetic macular edema", Ophthalmology, 121, pp.2247~2254 (2014)
- Kim LN, "Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration", Retina, 36, pp.1418~1431 (2016)
- Zhang Y, "Effects of aflibercept for neovascular age-related macular degeneration : a systematic review and meta-analysis of observational comparative studies", Invest Ophthalmol Vis Sci, 58, pp.5616~5627 (2017)
- Ashraf M, "Age-related macular degeneration : using morphological predictors to modify current treatment protocols", Acta Ophthalmol, 96, pp.120~133 (2018)
- Freund KB, "Treat-andextend regimens with anti-vegf agents in retinal diseases : a literature review and consensus recommendations", Retina, 35, pp.1489~1506 (2015)
- Chin-Yee D, "A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration", Br J Ophthalmol, 100, pp.914~917 (2016)
- Stewart MW, "Aflibercept(VEGF Trap-eye) : the newest anti-VEGF drug", Br J Ophthalmol, 96, pp.1157~1158 (2012)
- Kanda A, "Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy", Sci Rep, 5, pp.17946~ (2015)
- "Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group", Ophthalmology, 98, pp.786~806 (1991)
- Ip MS, "Long-term effects of ranibizumab on diabetic retinopathy severity and progression", Arch Ophthalmol, 130, pp.1145~1152 (2012)
- Staurenghi G, "Impact of baseline diabetic retinopathy severity scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies", Br J Ophthalmol, 102, pp.954~958 (2018)
- Silva R, "Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration : results with ranibizumab from the TREND Study", Ophthalmology, 125, pp.57~65 (2018)
- Payne JF, "Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema : TREX-DME 1 year outcomes", Ophthalmology, 124, pp.74~81 (2017)
- Prunte C, "Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema:the RETAIN study", Br J Ophthalmol, 100, pp.787~795 (2016)
- Avitabile T, "Aflibercept in the treatment of diabetic macular edema : a review and consensus paper", Eur J Ophthalmol, 27, pp.627~639 (2017)
- Pieramici D, "Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies", Ophthalmol Retina, 2, pp.558~566 (2018)
- Mitchell P, "Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies", Ophthalmol Retina, 2, pp.988~996 (2018)
- Hirano T, "Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal", grid laser photocoagulation, 2017, pp.61, 51~60